Prognosis of long-term survival considering disease-specific death in patients with chronic myeloid leukemia

Leukemia

Volumn 30, Issue 1, 2016, Pages 48-56

  Pfirrmann, M ^a   Baccarani, M ^b   Saussele, S ^c   Guilhot, J ^d   Cervantes, F ^e   Ossenkoppele, G ^f   Hoffmann, V S ^a   Castagnetti, F ^b   Hasford, J ^a   Hehlmann, R ^c   Simonsson, B ^g  

^a UNIVERSITY OF MUNICH   (Germany)

^b UNIVERSITY OF BOLOGNA   (Italy)

^c UNIVERSITY OF HEIDELBERG   (Germany)

^d POITIERS UNIVERSITY HOSPITAL   (France)

^e UNIVERSITY OF BARCELONA   (Spain)

^f VU UNIVERSITY AMSTERDAM   (Netherlands)

^g UPPSALA UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CYTARABINE; IMATINIB;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER EPIDEMIOLOGY; CANCER MORTALITY; CANCER PROGNOSIS; CANCER SURVIVAL; CHRONIC MYELOID LEUKEMIA; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE COURSE; DISEASE SPECIFIC SURVIVAL; DRUG EFFICACY; DYING; FEMALE; FOLLOW UP; HIGH RISK PATIENT; HUMAN; LONG TERM SURVIVAL; LOW RISK PATIENT; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; THROMBOCYTE COUNT; TREATMENT OUTCOME; ADOLESCENT; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MIDDLE AGED; MORTALITY; PROBABILITY; PROGNOSIS; VERY ELDERLY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; IMATINIB MESYLATE; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MIDDLE AGED; PROBABILITY; PROGNOSIS;

EID: 84953356030     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2015.261     Document Type: Article

References (41)

1. Deininger M, O'Brien SG, Guilhot F, Goldman JM, Hochhaus A, Hughes TP et al. International randomized study of interferon vs STI571 (IRIS) 8-year follow up: sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib. Blood 2009; 114: 462 (abstr 1126).
2. Hehlmann R, Muller MC, Lauseker M, Hanfstein B, Fabarius A, Schreiber A et al. Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib: results from the randomized CML-study IV. J Clin Oncol 2014; 32: 415-423.
3. Castagnetti F, Gugliotta G, Breccia M, Specchia G, Intermesoli T, Capucci A et al. Frontline treatment with imatinib mesylate in chronic myeloid leukemia patients in early chronic phase: a very long-term analysis by the GIMEMA CML Working Party. Blood 2013; 122: 258 (abstr 258).
4. Hasford J, Baccarani M, Hoffmann V, Guilhot J, Saussele S, Rosti G et al. Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score. Blood 2011; 118: 686-692.
5. Hoffmann VS, Baccarani M, Lindoerfer D, Castagnetti F, Turkina A, Zaritsky A et al. The EUTOS prognostic score: review and validation in 1288 patients with CML treated frontline with imatinib. Leukemia 2013; 27: 2016-2022.
6. Byar DP. Identification of prognostic factors. In: Buyse ME, Staquet MJ, Sylvester RJ (eds). Cancer Clinical Trials-Methods and Practice. Oxford University Press: Oxford, 1984; pp 423-441.
7. Hasford J, Pfirrmann M, Hehlmann R, Allan NC, Baccarani M, Kluin-Nelemans JC et al. A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group. J Natl Cancer Inst 1998; 90: 850-858.
8. O'Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003; 348: 994-1004.
9. Saglio G, Kim DW, Issaragrisil S, le Coutre P, Etienne G, Lobo C et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 2010; 362: 2251-2259.
10. Kantarjian H, Shah NP, Hochhaus A, Cortes J, Shah S, Ayala M et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2010; 362: 2260-2270.
11. Preudhomme C, Guilhot J, Nicolini FE, Guerci-Bresler A, Rigal-Huguet F, Maloisel F et al. Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia. N Engl J Med 2010; 363: 2511-2521.
12. Hehlmann R, Lauseker M, Jung-Munkwitz S, Leitner A, Muller MC, Pletsch N et al. Tolerability-adapted imatinib 800 mg/d versus 400 mg/d versus 400 mg/d plus interferon-{alpha} in newly diagnosed chronic myeloid leukemia. J Clin Oncol 2011; 29: 1634-1642.
13. Cortes JE, Kim D-W, Kantarjian HM, Brümmendorf TH, Dyagil I, Griskevicius L et al. Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial. J Clin Oncol 2012; 30: 3486-3492.
14. Radich JP, Kopecky KJ, Appelbaum FR, Kamel-Reid S, Stock W, Malnassy G et al. A randomized trial of dasatinib 100mg versus imatinib 400mg in newly diagnosed chronic-phase chronic myeloid leukemia. Blood 2012; 120: 3898-3905.
15. Sokal JE, Cox EB, Baccarani M, Tura S, Gomez GA, Robertson JE et al. Prognostic discrimination in 'good-risk' chronic granulocytic leukemia. Blood 1984; 63: 789-799.
16. Baccarani M, Deininger MW, Rosti G, Hochhaus A, Soverini S, Apperley JF et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia. 2013Blood 2013; 122: 872-884.
17. Therneau TM, Grambsch PM. Modeling Survival Data: Extending the Cox Model. Springer: New York, 2000.
18. Kalbfleisch JD, Prentice RL. The Statistical Analysis of Failure Time Data. Wiley: New York, 1980.
19. Choudhury JB. Non-parametric confidence interval estimation for competing risks analysis: application to contraceptive data. Stat Med 2002; 21: 1129-1144.
20. Gray RJ. A class of k-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 1988; 16: 1141-1154.
21. Pohar-Perme M, Stare J, Estève J. On estimation in relative survival. Biometrics 2012; 68: 113-120.
22. Pohar M, Stare J. Relative survival analysis in R. Comput Meth Prog Bio 2006; 81: 272-278.
23. Human Mortality Database: University of California, Berkeley (USA), and Max Planck Institute of Demographic Research (Germany): the human mortality database provides mortality and population data on various countries. 05/2014 update. Available at http://www.mortality.org/or http://www.humanmortality.de/.
24. Royston P, Sauerbrei W. Multivariable Model-Building: A Pragmatic Approach to Regression Analysis Based on Fractional Polynomials for Continuous Variables. John Wiley & Sons: Chichester, 2008.
25. Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 1999; 94: 496-509.
26. Kuk D, Varadhan R. Model selection in competing risks regression. Stat Med 2013; 32: 3077-3088.
27. Davison AC, Hinkley DV. Bootstrap Methods and Their application. Cambridge University Press: Cambridge, 1997.
28. Altman DG, Lausen B, Sauerbrei W, Schumacher M. Dangers of using 'optimal' cutpoints in the evaluation of prognostic factors. J Natl Cancer Inst 1994; 86: 829-835.
29. Silverman BW. Density Estimation for Statistics and Data Analysis. Chapman and Hall: London, 1986.
30. Sauerbrei W, Meier-Hirmer C, Benner A, Royston P. Multivariable regression model building by using fractional polynomials: description of SAS, STATA and R programs. Comput Stat Data An 2006; 50: 3464-3485.
31. Scrucca L, Santucci A, Aversa F. Regression modeling of competing risk using R: an in depth guide for clinicians. Bone Marrow Transpl 2010; 45: 1388-1395.
32. Deenik W, van der Holt B, Verhoef GE, Smit WM, Kersten MJ, Kluin-Nelemans HC et al. Dose-finding study of imatinib in combination with intravenous cytarabine: feasibility in newly diagnosed patients with chronic myeloid leukemia. Blood 2008; 111: 2581-2588.
33. Gugliotta G, Castagnetti F, Palandri F, Breccia M, Intermesoli T, Capucci A et al. Frontline imatinib treatment of chronic myeloid leukemia: no impact of age on outcome, a survey by the GIMEMA CML Working Party. Blood 2011; 117: 5591-5599.
34. Simonsson B, Gedde-Dahl T, Markevärn B, Remes K, Stentoft J, Almqvist A et al. Combination of pegylated IFN-2b with imatinib increases molecular response rates in patients with low-or intermediate-risk chronic myeloid leukemia. Blood 2011; 118: 3228-3235.
35. Cervantes F, López-Garrido P, Montero M-I, Jonte F, Martínez J, Hernández-Boluda J-C et al. Early intervention during imatinib therapy in patients with newly diagnosed chronic-phase chronic myeloid leukemia: a study of the Spanish PETHEMA group. Haematologica 2010; 95: 1317-1324.
36. Hoffmann VS, Baccarani M, Hasford J, Lindoerfer D, Burgstaller S, Sertic D et al. The EUTOS population-based registry: incidence and clinical characteristics of 2904 CML patients in 20 European Countries. Leukemia 2015; 29: 1336-1343.
37. Kalmanti L, Saussele S, Lauseker M, Proetel U, Muller MC, Hanfstein B et al. Younger patients with chronic myeloid leukemia do well in spite of poor prognostic indicators: results from the randomized CML study IV. Ann Hematol 2014; 93: 71-80.
38. Castagnetti F, Gugliotta G, Baccarani M, Breccia M, Specchia G, Levato L et al. Differences among young adults, adults and elderly chronic myeloid leukemia patients. Ann Oncol 2015; 26: 185-192.
39. Hasford J, Pfirrmann M, Hehlmann R, Shepherd P, Guilhot F, Mahon FX et al. Prognostic factors. In: Carella AM, Daley G, Eaves C, Goldman J, Hehlmann R (eds). Chronic Myeloid Leukemia-Biology and Treatment. Martin Dunitz: London, 2001; pp 205-223.
40. Scrucca L, Santucci A, Aversa F. Competing risk analysis using R: an easy guide for clinicians. Bone Marrow Transpl 2007; 40: 381-387.
41. Pfirrmann M, Hochhaus A, Lauseker M, Saussele S, Hehlmann R, Hasford J. Recommendations to meet statistical challenges arising from endpoints beyond overall survival in clinical trials on chronic myeloid leukemia. Leukemia 2011; 25: 1433-1438.